Delivery Order SPE2DB25D3018-SPE2DB25FUYEG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $5,358.11 and a firm fixed price structure. The contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of July 25, 2025. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $3,156.31 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 5 mg tablets (30-count packaging), with a completion date of August 27, 2025. This competitive award, issued on August 26, 2025, carries a firm fixed price and involves no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,070.46 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packages) with an ultimate completion date of August 15, 2025. This competitively awarded contract, issued on August 14, 2025, utilizes a firm fixed price structure with no set-aside designation. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package, valued at $1,036.29. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for the supply of Dapagliflozin 5 mg tablets (30-count units) valued at $10,269.40 under a firm fixed price contract. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $6,100.21 and an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting the federal government's pharmaceutical supply requirements. The order was placed to the company's place of performance in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 10, 2025, for the supply of Dapagliflozin 5 mg tablets in quantities of 30, valued at $1,646.96. This competitively awarded, firm fixed-price delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The contract carries no set-aside designation and is set for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $5,275.63. This competitive, non-set-aside delivery order represents a firm fixed price transaction with an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a $27,531.60 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count units). This firm fixed-price contract, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The delivery order specifies a place of performance in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 5 mg tablets in quantities of 30 units, with a ceiling value of $8,774.89. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB25D3018Indefinite Delivery Contract
- SPE2DB25D3018-SPE2DB25FUYEGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $38,360.32 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 5 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, competitively awarded delivery order was issued with no set-aside designation and represents performance at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp leverages its comprehensive IDC to supply a broad portfolio of medications and medical supplies supporting military and veteran healthcare systems. The dapagliflozin delivery order exemplifies the company's role in supplying specialty pharmaceutical products across multiple therapeutic domains, including diabetes medications, to the Defense Health Agency and other government healthcare organizations. This delivery order demonstrates the vendor's continued capability to fulfill federal medical procurement requirements through open competition and the flexible contracting mechanisms established under DLA's pharmaceutical prime vendor program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $38.4k | 8/7/25 |